The 5-year survival for @entity788 is usually less than 5%, and no treatment has demonstrated consistent effect on @entity1 survival and disease-related symptoms. Early studies with @entity136 suggested a modest antitumor activity with significant improvement in disease-related symptoms. This phase II study reports the activity of @entity136 on 33 consecutive @entity1 with unresectable @entity3123 . Twenty-three @entity1 had metastatic and 10 locally advanced unresectable disease. Twenty-six @entity1 had not received any previous treatment and seven had received first-line chemotherapy with @entity1487 . @entity136 1,000 mg/m2 was administered intravenously in 30 minutes in the first cycle once weekly for up to 7 weeks followed by 1 week rest; then in subsequent cycles, once weekly for 3 of every 4-week cycle. Four @entity1 obtained partial response (12%). Fifteen @entity1 (45%) had stable disease with a median duration of 32 weeks (range: 16-75 weeks), and 14 @entity1 experienced @entity74 . Median duration of response was 34.5 weeks (range: 19-50 weeks). Median survival was 33 weeks (range: 2-91 weeks). All 4 responding @entity1 and 14 of 15 (93%) @entity1 with stable disease had improvement in performance status and decrease in daily analgesic requirement. @entity137 was mild and mainly consisted of moderate and rapidly reversible myelosuppression. We conclude that @entity136 chemotherapy was very well tolerated and determined a significant clinical improvement with modest antitumoral activity in @entity1 with advanced @entity788 .

XXXX in advanced @entity788 : a phase II trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
